Replaces Prod. #: ALX-340-055
Endogenous anandamide-like compound. Lacks affinity for CB1 receptors (Ki>10µM), TRPV1 (EC50>10µM) and anandamide uptake (IC50>50µM), but inhibits fatty acid amide hydrolase (FAAH) (IC50=8.5µM-50µM, depending on cell type and species). Displays anti-inflammatory and analgesic activity. Identified as an insulin secretagogue in a primary β-cell-based functional assay. Represents a new class of "lipoamino acids".
Product Details
| Formula: | C22H35NO3 |
| |
| MW: | 361.5 |
| |
| Source: | Synthetic. |
| |
| CAS: | 179113-91-8 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | White waxy solid. |
| |
| Solubility: | Soluble in DMSO or 100% ethanol. 2mg/ml soluble in PBS (pH 7.2). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from air. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.: D. McHugh, et al.; BMC Neurosci.
11, 44 (2010),
Abstract;
Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18: M. Kohno, et al.; BBRC
347, 827 (2006),
Abstract;
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase: M. Grazia Cascio, et al.; BBRC
314, 192 (2004),
Abstract;
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain: S.M. Huang, et al.; J. Biol. Chem.
276, 42639 (2001),
Abstract;
Oxidative metabolism of anandamide: S.H. Burstein, et al.; Prostaglandins Other Lipid Mediat.
61, 29 (2000),
Abstract;
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor: T. Sheskin, et al.; J. Med. Chem.
40, 659 (1997),
Abstract;
